Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers.
It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution.
The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC.
The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104.
UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.92 Increased by +5.15% | -0.80 Decreased by -15.72% |
| Mar 12, 25 | -0.80 Decreased by -11.11% | -0.72 Decreased by -11.11% |
| Nov 6, 24 | -0.55 Increased by +19.12% | -0.82 Increased by +32.93% |
| Aug 13, 24 | -0.91 Increased by +11.65% | -0.83 Decreased by -9.64% |
| May 13, 24 | -0.97 Increased by +25.38% | -0.87 Decreased by -11.49% |
| Mar 14, 24 | -0.72 Increased by +40.98% | -0.68 Decreased by -5.88% |
| Nov 14, 23 | -0.68 Increased by +39.82% | -0.85 Increased by +20.00% |
| Aug 10, 23 | -1.03 Increased by +12.71% | -1.14 Increased by +9.65% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 20.25 M Increased by +7.84% | -43.84 M Decreased by -35.80% | Decreased by -216.47% Decreased by -25.92% |
| Dec 31, 24 | 24.57 M Increased by +4.40% | -37.51 M Decreased by -44.19% | Decreased by -152.71% Decreased by -38.11% |
| Sep 30, 24 | 25.20 M Increased by +20.87% | -23.67 M Decreased by -8.20% | Decreased by -93.93% Increased by +10.48% |
| Jun 30, 24 | 21.85 M Increased by +3.35% | -33.40 M Decreased by -38.39% | Decreased by -152.89% Decreased by -33.90% |
| Mar 31, 24 | 18.78 M Increased by +9.24% | -32.29 M Decreased by -6.86% | Decreased by -171.91% Increased by +2.18% |
| Dec 31, 23 | 23.53 M Increased by +30.06% | -26.02 M Increased by +7.90% | Decreased by -110.57% Increased by +29.19% |
| Sep 30, 23 | 20.85 M Increased by +29.54% | -21.88 M Increased by +15.30% | Decreased by -104.93% Increased by +34.61% |
| Jun 30, 23 | 21.14 M Increased by +27.31% | -24.14 M Increased by +9.57% | Decreased by -114.18% Increased by +28.97% |